Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIA Study of probucol in mild cognitive impairment or mild dementia due to Alzheimer's disease
ACTRN12621000726853Phase 2Recruiting
- Sponsor
- Curtin University
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Lorelco treatment with Placebo control (2 arms). Primary endpoint: Cognitive performance by ADAS-Cog. Started Jan 2022; status: recruiting.
02
Drugs
probucol
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ACTRN12621000726853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000726853.